BASHIR AHMED: Open Payments
NPI 1659537827 · FAIRVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$653 in 48 payments from 11 companies in 2025. Trend: 2023 $915 · 2024 $1,013 · 2025 $653
Food & beverage: $653
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $166 |
| ABBVIE INC. | 14 | $163 |
| Otsuka America Pharmaceutical, Inc. | 13 | $138 |
| Alkermes, Inc. | 3 | $49 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Bausch Health US, LLC | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: CAPLYTA, VRAYLAR, REXULTI, LYBALVI, INVEGA SUSTENNA, APLENZIN, Xelstrym, COBENFY.
Industry payments across TX — which companies pay providers there.
